Rockwell Medical Analyst Ratings
Rockwell Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 285.96% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 07/17/2023 | 285.96% | HC Wainwright & Co. | $9 → $11 | Maintains | Buy |
| 05/30/2023 | 215.79% | HC Wainwright & Co. | $7 → $9 | Maintains | Buy |
| 05/02/2023 | 145.61% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/04/2023 | 145.61% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/13/2023 | 145.61% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 02/08/2023 | 145.61% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 08/30/2022 | 180.7% | HC Wainwright & Co. | $3 → $8 | Maintains | Buy |
| 01/18/2022 | 5.26% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 09/07/2021 | 75.44% | HC Wainwright & Co. | $5.5 → $5 | Maintains | Buy |
| 02/08/2021 | 92.98% | HC Wainwright & Co. | $9 → $5.5 | Maintains | Buy |
| 04/07/2020 | 215.79% | HC Wainwright & Co. | $11 → $9 | Maintains | Buy |
| 11/12/2019 | 110.53% | Piper Sandler | $10 → $6 | Maintains | Overweight |
| 06/25/2019 | 285.96% | Cantor Fitzgerald | → $11 | Initiates Coverage On | → Overweight |
| 06/24/2019 | 250.88% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 10/19/2018 | 285.96% | IFS Securities | → $11 | Downgrades | Strong Buy → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/15/2023 | 285.96% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
| 07/17/2023 | 285.96% | HC Wainwright & Co. | 9 美元 → 11 美元 | 维护 | 购买 |
| 05/30/2023 | 215.79% | HC Wainwright & Co. | 7 美元 → 9 美元 | 维护 | 购买 |
| 05/02/2023 | 145.61% | HC Wainwright & Co. | → 7 美元 | 重申 | → 购买 |
| 04/04/2023 | 145.61% | HC Wainwright & Co. | → 7 美元 | 重申 | → 购买 |
| 02/13/2023 | 145.61% | HC Wainwright & Co. | → 7 美元 | 重申 | → 购买 |
| 02/08/2023 | 145.61% | HC Wainwright & Co. | 8 美元 → 7 美元 | 维护 | 购买 |
| 08/30/2022 | 180.7% | HC Wainwright & Co. | 3 美元 → 8 美元 | 维护 | 购买 |
| 01/18/2022 | 5.26% | HC Wainwright & Co. | 5 美元 → 3 美元 | 维护 | 购买 |
| 09/07/2021 | 75.44% | HC Wainwright & Co. | 5.5 美元 → 5 美元 | 维护 | 购买 |
| 02/08/2021 | 92.98% | HC Wainwright & Co. | 9 美元 → 5.5 美元 | 维护 | 购买 |
| 2020 年 7 月 4 日 | 215.79% | HC Wainwright & Co. | 11 美元 → 9 美元 | 维护 | 购买 |
| 2019 年 12 月 11 日 | 110.53% | 派珀·桑德勒 | 10 美元 → 6 美元 | 维护 | 超重 |
| 06/25/2019 | 285.96% | 坎托·菲茨杰拉德 | → 11 美元 | 启动覆盖开启 | → 超重 |
| 06/24/2019 | 250.88% | 派珀·桑德勒 | → 10 美元 | 启动覆盖开启 | → 超重 |
| 2018 年 10 月 19 日 | 285.96% | IFS 证券 | → 11 美元 | 降级 | 强势买入 → 跑赢大盘 |
What is the target price for Rockwell Medical (RMTI)?
罗克韦尔医疗（RMTI）的目标价格是多少？
The latest price target for Rockwell Medical (NASDAQ: RMTI) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $11.00 expecting RMTI to rise to within 12 months (a possible 285.96% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月15日公布了罗克韦尔医疗（纳斯达克股票代码：RMTI）的最新目标股价。这家分析公司将目标股价定为11.00美元，预计RMTI将在12个月内升至12个月内（可能上涨285.96％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Rockwell Medical (RMTI)?
罗克韦尔医疗（RMTI）的最新分析师评级是多少？
The latest analyst rating for Rockwell Medical (NASDAQ: RMTI) was provided by HC Wainwright & Co., and Rockwell Medical reiterated their buy rating.
Rockwell Medical（纳斯达克股票代码：RMTI）的最新分析师评级由HC Wainwright & Co. 提供，罗克韦尔医疗重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Rockwell Medical (RMTI)?
罗克韦尔医疗（RMTI）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rockwell Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rockwell Medical was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Rockwell Medical的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Rockwell Medical的最后一次评级是在2023年8月15日提交的，因此您应该预计下一个评级将在2024年8月15日左右公布。
Is the Analyst Rating Rockwell Medical (RMTI) correct?
分析师对罗克韦尔医疗（RMTI）的评级是否正确？
While ratings are subjective and will change, the latest Rockwell Medical (RMTI) rating was a reiterated with a price target of $0.00 to $11.00. The current price Rockwell Medical (RMTI) is trading at is $2.85, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但罗克韦尔医疗（RMTI）的最新评级得到了重申，目标股价为0.00美元至11.00美元。罗克韦尔医疗（RMTI）目前的交易价格为2.85美元，在分析师的预测区间内。